Literature DB >> 20582534

From the bench to the bed side: PI3K pathway inhibitors in clinical development.

Saveur-Michel Maira1, Peter Finan, Carlos Garcia-Echeverria.   

Abstract

A number of intracellular kinase components of the PI3K/Akt/mTOR pathway have been targeted over the past few years, leading to a new generation of anticancer agents that effectively and specifically disrupt this pathway in tumor cells. Here, progress in the identification and clinical evaluation of compounds designed to modulate the enzymatic activity of PI3K, Akt, mTOR, and Hsp90 is reviewed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20582534     DOI： 10.1007/82_2010_60

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  13 in total

1.  Sprouty-Related Ena/Vasodilator-Stimulated Phosphoprotein Homology 1-Domain-Containing Protein-2 Critically Regulates Influenza A Virus-Induced Pneumonia.

Authors:  Toshihiro Ito; Junya Itakura; Sakuma Takahashi; Miwa Sato; Megumi Mino; Soichiro Fushimi; Masao Yamada; Tuneo Morishima; Steven L Kunkel; Akihiro Matsukawa
Journal:  Crit Care Med       Date:  2016-07       Impact factor: 7.598

Review 2.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  Targeting survival pathways in chronic myeloid leukaemia stem cells.

Authors:  A Sinclair; A L Latif; T L Holyoake
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

4.  Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.

Authors:  Sweta Maheshwari; Michelle S Miller; Robert O'Meally; Robert N Cole; L Mario Amzel; Sandra B Gabelli
Journal:  J Biol Chem       Date:  2017-07-04       Impact factor: 5.157

5.  HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.

Authors:  Samuel K Shimp; Carl D Parson; Nicole L Regna; Alicia N Thomas; Cristen B Chafin; Christopher M Reilly; M Nichole Rylander
Journal:  Inflamm Res       Date:  2012-02-12       Impact factor: 4.575

6.  Nucleoporin 37 promotes the cell proliferation, migration, and invasion of gastric cancer through activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Jishui Zhang; Wenhao Lv; Yagang Liu; Weihua Fu; Baosheng Chen; Qiutong Ma; Xin Gao; Xiuxia Cui
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-12-09       Impact factor: 2.416

7.  Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.

Authors:  Bedri Karakas; Dilek Colak; Namik Kaya; Hazem Ghebeh; Abeer Al-Qasem; Fawziah Hendrayani; Mohamed Toulimat; Taher Al-Tweigeri; Ben Ho Park; Abdelilah Aboussekhra
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

8.  Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo.

Authors:  K Schuster; J Zheng; A A Arbini; C C Zhang; P P Scaglioni
Journal:  Blood Cancer J       Date:  2011-09-02       Impact factor: 11.037

9.  Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.

Authors:  Jorge L Jacot; David Sherris
Journal:  J Ophthalmol       Date:  2011-10-30       Impact factor: 1.909

10.  Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Authors:  Kerstin Maria Kampa-Schittenhelm; Michael Charles Heinrich; Figen Akmut; Katharina Henriette Rasp; Barbara Illing; Hartmut Döhner; Konstanze Döhner; Marcus Matthias Schittenhelm
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.